McDermott Represents Iron Path Capital in PureTech Scientific’s $137 Million Acquisition of Glycolic Acid Business from The Chemour Company
International law firm McDermott Will & Emery represented Iron Path Capital, a private equity firm focused on lower-middle market investments across the specialty industrial and healthcare sectors, in its backed company PureTech Scientific’s acquisition of The Chemours Company’s Glycolic Acid business. With this acquisition, PureTech Scientific is positioning itself to become the global leader in organic synthesis of ultra-high purity alpha hydroxy acids for the Life Sciences and Specialty Chemical industries.
The transaction was announced on June 1, 2023 and is expected to close by the third quarter of 2023, subject to regulatory approvals and other customary closing conditions.
McDermott’s private equity practice is among the top four most active PE law firms globally and in the US with more than 160 dedicated private equity lawyers in 21 locations globally. In addition to being Pitchbook’s top Healthcare PE firm for a fifth consecutive year and fifth in both IT and financial services private equity, we are named Energy & Industrials Law Firm of the Year (Large Cap) by The Deal, Top 10 in PE Buyouts by MergerMarket and Top 10 in US Mid-Market by Bloomberg. Learn more about our PE practice by visiting pe.mwe.com.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.